# Anti-PD-1 and VEGF Bispecific Antibody AK112 in Combination With Chemotherapy in Patients With ES-SCLC

> **NCT05116007** · PHASE1 · COMPLETED · sponsor: **Akeso** · enrollment: 35 (actual)

## Conditions studied

- SCLC, Extensive Stage

## Interventions

- **DRUG:** AK112
- **DRUG:** Etoposide
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT05116007
- **Lead sponsor:** Akeso
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-29
- **Primary completion:** 2023-12-04
- **Final completion:** 2023-12-04
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2024-05-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05116007

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05116007, "Anti-PD-1 and VEGF Bispecific Antibody AK112 in Combination With Chemotherapy in Patients With ES-SCLC". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05116007. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*